Search results for: Oncology
Filter search results
New OHE Study Compares Decisions by Five HTA Agencies on Oncology Meds
31 January 2013
…K.K., Mestre-Ferrandiz, J., Towse, A. and Smyth, E.H. (2013) A review of health technology appraisals: Case studies in oncology. International Journal of Technology Assessment in Health Care. FirstView article. doi:10.1017/S0266462312000669. (subscription required)…
The Expanding Value Footprint of Oncology Treatments
13 May 2014
…A., 2014. The expanding value footprint of oncology treatments. Consulting report. London: Office of Health Economics. For additional information about this study and OHE Consulting, please contact Jorge Mestre-Ferrandiz. …
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
3 July 2018
…Technology Assessments in Oncology. OHE Consulting Report, London: Office of Health Economics. RePEc Related Research Lorgelly, P.K. and Neri, M. 2018. Survivorship Burden for Individuals, Households and Society:…
Assessment and Appraisal of Oncology Medicines: NICE’s Approach and International HTA Experience
1 February 2009
Lower usage of cancer medicines in the UK compared to other countries has created questions, including whether the current approach by NICE to assessing cancer medicines is an important factor…
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
1 June 2018
Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such as immunotherapies….
The Expanding Value Footprint of Oncology Treatments
1 May 2014
The cohort of cancer drugs included are the ten approved by the EMA during 2003–2005. This time period was chosen based on the assumption that cancer drugs on the market…
Routine Funding in the UK NHS of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
18 December 2017
…Scotland, products used in oncology and orphan disease were associated with a lower odds of receiving a positive HTA recommendation compared with non-oncology products and products which did not receive…
Lung Cancer’s Biggest Test: How Can We Mobilise NGS Testing to Transform Lung Cancer Care?
7 December 2023, 12:00am
…also Head of the Immuno-Oncology group at UNICANCER R&D. She is a member of several pathology and oncology societies, including the European Society for Medical Oncology. Frederique has over 400…
Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
1 December 2017
…and made mandatory for orphan and oncology medicines. We analysed routine funding in the NHS for new medicines recently authorised via the centralised procedure with a particular focus on oncology…